Skip to main content
. 2021 Jan 11;18(1):e1003454. doi: 10.1371/journal.pmed.1003454

Fig 3. Progression-free survival 2.

Fig 3

(A) Progression-free survival 2 for the KRdc group compared to the Tdc/Rdc control group. Note that medians and confidence intervals were inestimable. (B) Progression-free survival 2 for the KRdc group compared to the Tdc and Rdc control groups separately. Note that medians and confidence intervals were inestimable. KRdc, carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide; Rdc, lenalidomide, dexamethasone, and cyclophosphamide; Tdc, thalidomide, dexamethasone, and cyclophosphamide.